S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
The single greatest medical breakthrough of all time? (Ad)
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
The single greatest medical breakthrough of all time? (Ad)
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Disney, DeSantis legal fights ratchet up as company demands documents from Florida governor
The single greatest medical breakthrough of all time? (Ad)
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
The single greatest medical breakthrough of all time? (Ad)
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
The single greatest medical breakthrough of all time? (Ad)
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Disney, DeSantis legal fights ratchet up as company demands documents from Florida governor
The single greatest medical breakthrough of all time? (Ad)
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
The single greatest medical breakthrough of all time? (Ad)
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
The single greatest medical breakthrough of all time? (Ad)
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Disney, DeSantis legal fights ratchet up as company demands documents from Florida governor
The single greatest medical breakthrough of all time? (Ad)
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
The single greatest medical breakthrough of all time? (Ad)
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
The single greatest medical breakthrough of all time? (Ad)
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Disney, DeSantis legal fights ratchet up as company demands documents from Florida governor
The single greatest medical breakthrough of all time? (Ad)
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
NASDAQ:AMRS

Amyris (AMRS) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$0.05
$0.06
50-Day Range
$0.05
$1.17
52-Week Range
$0.05
$4.86
Volume
46.75 million shs
Average Volume
12.59 million shs
Market Capitalization
$18.47 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.06

Amyris MarketRank™ Forecast

Analyst Rating
Hold
2.20 Rating Score
Upside/​Downside
6,014.3% Upside
$3.06 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.00mentions of Amyris in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.75) to ($0.73) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.74 out of 5 stars

Basic Materials Sector

141st out of 168 stocks

Specialty Chemicals Industry

1st out of 1 stocks


AMRS stock logo

About Amyris (NASDAQ:AMRS) Stock

Amyris, Inc. operates as a biotechnology company in Europe, North America, Asia, South America, and internationally. It creates, manufactures, and commercializes consumer products and ingredient, including clean beauty, personal care, and health and wellness consumer products; and ingredients to the flavor and fragrance, nutrition, food and beverage, and clean beauty and personal care end markets. The company markets its products under the Biossance, JVN, Rose Inc., Pipette, Costa Brazil, OLIKA, Purecane, Terasana, MenoLabs, EcoFabulous, Stripes, and 4U by Tia brand names. It has a collaboration and license agreement with the Infectious Disease Research Institute for the development of a COVID-19 vaccine. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was incorporated in 2003 and is headquartered in Emeryville, California. On August 9, 2023, Amyris, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.


AMRS Stock News Headlines

Gevo's Valentine's Day Massacre
Amyris, Inc. (AMRS) Soars: Stock Up 16.0%
Better Than Oil Stocks
The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment. 
Firm Retention Summary: Amyris
Why Amyris Stock Is Rocketing Higher
Better Than Oil Stocks
The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment. 
AMRS Stock Surges 152% as Amyris Files for Bankruptcy
Biotech firm Amyris files for bankruptcy in US
Amyris files for Chapter 11 bankruptcy
AMRS - Amyris, Inc.
John Melo Exits Amyris
Amyris Chief Executive John Melo Resigns
See More Headlines
Receive AMRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amyris and its competitors with MarketBeat's FREE daily newsletter.

AMRS Company Calendar

Last Earnings
11/08/2021
Today
10/01/2023
Next Earnings (Estimated)
11/06/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Specialty Chemicals
Sub-Industry
Oil & Gas Refining & Marketing
Current Symbol
NASDAQ:AMRS
CUSIP
03236M10
Employees
1,598
Year Founded
2003

Price Target and Rating

Average Stock Price Forecast
$3.06
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$0.65
Forecasted Upside/Downside
+6,014.3%
Consensus Rating
Hold
Rating Score (0-4)
2.20
Research Coverage
5 Analysts

Profitability

Net Income
$-528,510,000.00
Net Margins
-229.12%
Pretax Margin
-235.25%

Debt

Sales & Book Value

Annual Sales
$269.85 million
Book Value
($1.52) per share

Miscellaneous

Free Float
235,299,000
Market Cap
$18.47 million
Optionable
Optionable
Beta
1.19

Social Links

5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Hermanus KieftenbeldMr. Hermanus Kieftenbeld (Age 57)
    Interim CEO, CFO & Chief Admin. Officer
    Comp: $644.71k
  • Mr. Eduardo AlvarezMr. Eduardo Alvarez (Age 59)
    Chief Operating Officer
    Comp: $687.62k
  • Ms. Elizabeth E. Dreyer CPA (Age 61)
    Chief Accounting Officer & Corp. Controller
  • Mr. Peter DeNardo
    Sr. Director of Investor Relations & Corp. Communications
  • Ms. Doris Choi (Age 45)
    Gen. Counsel & Sec.
  • Ms. Christine Ofori
    Chief People Officer
  • Mr. Jim Iacoponi
    Sr. VP of Nutrition Ingredients
  • Ms. Beth Baker Bannerman
    Chief Engagement & Sustainability Officer
  • Ms. Daya Fields
    Pres of Pipette & Purecane
  • Ms. Annie Tsong
    Chief Product & Technology Strategy Officer













AMRS Stock - Frequently Asked Questions

Should I buy or sell Amyris stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amyris in the last year. There are currently 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" AMRS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMRS, but not buy additional shares or sell existing shares.
View AMRS analyst ratings
or view top-rated stocks.

What is Amyris' stock price forecast for 2023?

5 Wall Street research analysts have issued 1 year price objectives for Amyris' stock. Their AMRS share price forecasts range from $0.65 to $6.00. On average, they expect the company's share price to reach $3.06 in the next year. This suggests a possible upside of 6,014.3% from the stock's current price.
View analysts price targets for AMRS
or view top-rated stocks among Wall Street analysts.

When is Amyris' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our AMRS earnings forecast
.

How were Amyris' earnings last quarter?

Amyris, Inc. (NASDAQ:AMRS) posted its quarterly earnings results on Monday, November, 8th. The biotechnology company reported ($0.11) earnings per share for the quarter, topping analysts' consensus estimates of ($0.15) by $0.04. The biotechnology company had revenue of $47.90 million for the quarter, compared to analyst estimates of $64.21 million. The business's quarterly revenue was up 39.7% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.41) EPS.

What ETFs hold Amyris' stock?

ETFs with the largest weight of Amyris (NASDAQ:AMRS) stock in their portfolio include AXS Cannabis ETF (THCX).VegTech Plant-based Innovation & Climate ETF (EATV).

When did Amyris' stock split?

Amyris's stock reverse split on the morning of Tuesday, June 6th 2017. The 1-15 reverse split was announced on Tuesday, June 6th 2017. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 5th 2017. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What is John Melo's approval rating as Amyris' CEO?

84 employees have rated Amyris Chief Executive Officer John Melo on Glassdoor.com. John Melo has an approval rating of 54% among the company's employees. This puts John Melo in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 77.0% of employees surveyed would recommend working at Amyris to a friend.

What other stocks do shareholders of Amyris own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amyris investors own include Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), Nokia Oyj (NOK), Gevo (GEVO), Inovio Pharmaceuticals (INO), Pfizer (PFE), AT&T (T), Dynavax Technologies (DVAX), Novavax (NVAX) and NVIDIA (NVDA).

What is Amyris' stock symbol?

Amyris trades on the NASDAQ under the ticker symbol "AMRS."

What is Amyris' stock price today?

One share of AMRS stock can currently be purchased for approximately $0.05.

How much money does Amyris make?

Amyris (NASDAQ:AMRS) has a market capitalization of $18.47 million and generates $269.85 million in revenue each year. The biotechnology company earns $-528,510,000.00 in net income (profit) each year or ($1.93) on an earnings per share basis.

How many employees does Amyris have?

The company employs 1,598 workers across the globe.

How can I contact Amyris?

Amyris' mailing address is 5885 HOLLIS STREET SUITE 100, EMERYVILLE CA, 94608. The official website for the company is amyris.com. The biotechnology company can be reached via phone at (510) 450-0761, via email at investor@amyris.com, or via fax at 510-225-2645.

This page (NASDAQ:AMRS) was last updated on 10/1/2023 by MarketBeat.com Staff

My Account -